Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310984 | 0.85 | SIGMAR1 (0.38) | RAD52GNAO1GNAI3GNAI1TMEM97 | |
| Hydrochloric Acid SCHEMBL310946 | 0.83 | SIGMAR1 (0.37) | SMN1; SMN2HPGDKMT2ARAD52GNAO1 | |
| SCHEMBL6280566 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDKMT2AGNAO1GNAI3 | |
| SCHEMBL21367143 | 0.81 | SLC18A3 (0.40) | SMN1; SMN2HPGDKMT2AHTR6RAD52 | |
| Hydrochloric Acid SCHEMBL27178798 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2HPGDKMT2AHTR6RAD52 | |
| SCHEMBL211275 | 0.79 | — | — | |
| SCHEMBL22962672 | 0.78 | GNAO1 (0.39) | SMN1; SMN2HPGDKMT2AHTR6RAD52 | |
| Hydrochloric Acid SCHEMBL311770 | 0.77 | POLB (0.48) | SMN1; SMN2RAD52POLBCXCR4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2488007 | 0.77 | POLB (0.48) | SMN1; SMN2RAD52POLBCXCR4SIGMAR1 | |
| SCHEMBL20323638 | 0.77 | HRH3 (0.41) | SMN1; SMN2HPGDKMT2AGNAO1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | BEIJING PHYTOVENT PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4477225-A1 | USE OF SARSASAPOGENIN STRUCTURE-BASED DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | Beijing Phytovent Pharmaceutical Technology Co., Ltd. (CN) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023155757-A1 | USE OF SARSASAPOGENIN STRUCTURE-BASED DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | 北京清博汇能医药科技有限公司 | 2023-08-24 | — | — | WO | disclosed |
| CN-116621912-A | Derivatives based on sarsasapogenin structure and use of pharmaceutical compositions thereof | 北京清博汇能医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | MAVS, NLN, TFAM | SMN1; SMN2 364/4885HPGD 244/4885KMT2A 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.